Open AccessASP 8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
Author(s) -
Azuma Koichi,
Nishio Makoto,
Hayashi Hidetoshi,
Kiura Katsuyuki,
Satouchi Miyako,
Sugawara Shunichi,
Hida Toyoaki,
Iwamoto Yasuo,
Inoue Akira,
Takeda Koji,
Ikeda Satoshi,
Nakagawa Tomoki,
Takeda Kentaro,
Asahina Seitaro,
Komatsu Kanji,
Morita Satoshi,
Fukuoka Masahiro,
Nakagawa Kazuhiko
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13651
Subject(s) - t790m , medicine , tolerability , lung cancer , discontinuation , resistance mutation , epidermal growth factor receptor , tyrosine kinase inhibitor , adverse effect , mutation , gastroenterology , oncology , point mutation , tyrosine kinase , clinical endpoint , cancer , gefitinib , clinical trial , receptor , biology , genetics , gene , polymerase chain reaction , reverse transcriptase
Epidermal growth factor receptor ( EGFR ) activating mutations occur in approximately 50% of East Asian patients with non‐small‐cell lung cancer ( NSCLC ) and confer sensitivity to tyrosine kinase inhibitors ( TKI s). ASP 8273 is an irreversible EGFR ‐ TKI , given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation‐positive NSCLC . Epidermal growth factor receptor‐ TKI ‐naïve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open‐label, single‐arm, phase II study (ClinicalTrials.gov identifier NCT 02500927). Patients received ASP 8273 300 mg once daily until discontinuation criteria were met. The primary end‐point was to determine the safety of ASP 8273 300 mg; the secondary end‐point was antitumor activity defined by RECIST version 1.1. Thirty‐one patients (12 men and 19 women; median age, 64 years [range, 31‐82 years]) with EGFR mutation‐positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81%) were still on study. Of the 31 patients, 27 (87%) had an exon 19 deletion (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, and two (7%) had an L861Q mutation. Five patients (16%) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment‐emergent adverse event was diarrhea (n = 24, 77%). All patients had at least one post‐baseline scan; one patient (3%) achieved a confirmed complete response, 13 (42%) had a confirmed partial response, and 15 (48%) had confirmed stable disease (disease control rate, 94% [n = 29/31]) per investigator assessment. Once‐daily ASP 8273 at 300 mg was generally well tolerated and showed antitumor activity in TKI ‐naïve Japanese patients with EGFR mutation‐positive NSCLC .